Evozyne announced the closing of an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform ...
Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, tod...
“We are thrilled to receive marketing approval for AVT04 in Japan, which will be Alvotech’s second marketed biosimilar,” said Robert Wess...
Subcutaneous EPKINLYTM (epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/r...
Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational ...
CBM brings extensive cell and gene therapy expertise to SK pharmteco portfolio and continues SK pharmteco’s strategy to deliver end-to-end, multi-mod...
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...
Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa Spain-based gl...
- Pharmanovia acquires 11 CNS brands, including Frisium® (clobazam) and Gardenal® (phenobarbital) - The portfolio is available in more than 60 mar...
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigim...
Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the collaboration with Eurofins Genomics to bolster its offerings in the fields...
“Since our founding in 2017, Herophilus’s vision has been to leverage the parallel revolutions in human complex in vitro brain models, scaled l...
The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...
Second commercialized product strengthens Clover’s leading respiratory vaccine franchise and financial profile-- Clover Biopharmaceutica...
© 2024 Biopharma Boardroom. All Rights Reserved.
